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Abstract
 
We have directly compared the efficacy of two immunotherapeutic strategies for the treatment
of cancer: “vaccination” of tumor-bearing mice with genetically modified dendritic cells
(DCs), and vaccination with genetically modified tumor cells. Using several different preexist-
ing tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen
(human melanoma-associated gene [MAGE]-1), we found that vaccination with bone mar-
row–derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to
a dramatic decrease in the number of metastases in a lung metastasis model, and led to pro-
longed survival and some long-term cures in a subcutaneous preexisting tumor model. In con-
trast, vaccination with granulocyte/macrophage colony-stimulating factor (GM-CSF)–trans-
duced tumor cells, previously shown to induce potent antitumor immunity in standard tumor
challenge assays, led to a decreased therapeutic effect in the metastasis model and no effect in
the subcutaneous tumor model. Further engineering of DCs to express either GM-CSF, tumor
 
necrosis factor 
 
a
 
, or CD40 ligand via retroviral-mediated gene transfer, led to a significantly in-
creased therapeutic effect in the subcutaneous tumor model. The immunological mechanism,
 
as shown for GM-CSF–transduced DCs, involves MAGE-1–specific CD4
 
1
 
 and CD8
 
1
 
 T cells.
Expression of GM-CSF by DCs led to enhanced cytotoxic T lymphocyte activity, potentially
mediated by increased numbers of DCs in draining lymph nodes. Our results suggest that clin-
ical studies involving the vaccination with genetically modified DCs may be warranted.
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Introduction
 
Successful treatment of malignant diseases by the enhance-
ment of antitumor immunity has been a long-standing goal
of immunological research. Over the past decade, advances
in our understanding of the role that specific cytokines and
other gene products play in determining the outcome of an
immune response have particularly rekindled optimism that
immunotherapeutic approaches to the treatment of cancer
will ultimately succeed. Among the many different immu-
notherapeutic strategies that are currently being evaluated,
therapeutic vaccination with genetically modified tumor
 
cells and vaccination with dendritic cells (DCs)
 
1
 
 manipu-
lated to present specific tumor antigens have attracted par-
ticular attention (1, 2). In the case of studies involving the
use of gene-modified tumor cells as therapeutic vaccines, a
large number of different gene products have been shown
to possess the ability to stimulate antitumor immunity (3–
8). Interestingly, however, in studies that directly compare
the relative immunostimulatory activities of different gene
products in nonimmunogenic tumor challenge models, one
specific gene product, GM-CSF, appears to possess particu-
larly potent activity (9). Early clinical studies suggest that
GM-CSF may have significant biological activity in pa-
tients as well (10). Although the mechanism by which
GM-CSF mediates antitumor immunity is still not com-
pletely understood, a variety of evidence suggests that se-
cretion of cytokine local to the injected tumor cells results
in the accumulation of large numbers of DCs, and may
augment the antigen presentation functions of the cells.
In parallel to studies with cytokine-expressing tumor
cells, various groups have also evaluated the direct use of
DCs as therapeutic cancer vaccines. Early studies demon-
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Abbreviations used in this paper:
 
 Ad, adenovirus; DC, dendritic cell; EF,
embryonic fibroblast; GFP, green fluorescent protein; IRES, internal ri-
bosomal entry site; MAGE, melanoma-associated gene. 
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strated that murine DCs pulsed with peptides or protein
can protect mice against a lethal challenge with tumor cells
(11–13). More recently, a variety of preparations of DCs
have been shown to stimulate antitumor immunity, includ-
ing DCs loaded with peptide (14) or tumor cell extracts
(15), fused with tumor cells (16), transduced with RNA
isolated from tumor tissues (17, 18), or transduced by viral
vectors (19, 20).
Because the immunotherapeutic strategies involving GM-
CSF–expressing tumor cells and DCs both appear to po-
tently stimulate antitumor immunity and likely act through
a common immunologic mechanism, we were interested
in determining the relative efficacy of the two strategies in
a direct comparative study. Here we report a side by side
comparison of the antitumor activity of genetically modi-
fied DCs engineered to express a target tumor antigen ver-
sus cytokine-expressing tumor cells, and examine the effects
of further genetic modifications of transduced DCs on their
therapeutic efficacy.
 
Materials and Methods
 
Animals and Cell Lines.
 
Specific pathogen-free, age-matched
(8–10 wk old) female C57BL/6 mice and congenic CD4
 
2/2
 
 and
CD8
 
2/2
 
 mice were obtained from The Jackson Laboratory. B16–
melanoma-associated gene (MAGE)-1 is a subclone of B16F10
cells stably transduced with a retrovirus encoding the human
MAGE-1 gene (21). B16-MAGE-1 was further transduced with
the retroviral vectors CMMP-GM-CSF, SFG-IL12 (22), or SFG-
CD80 to yield B16M-GM-CSF, B16M-IL12, and B16M-CD80,
respectively. B16M-CD40L was generated by transduction of
B16M cells with MMP-CD40L (CD40L cDNA; provided by R.
Geha, Children’s Hospital, Boston, MA). Embryonic fibroblast
(EF) cells were obtained from congenic mouse embryos and ret-
rovirally transduced with SFG-MAGE-1. Tumor cell lines were
maintained in DME (GIBCO BRL) supplemented with 10%
(vol/vol) heat-inactivated FCS, 2 mmol/liter glutamine, 50 U/ml
penicillin and streptomycin (GIBCO BRL). NIH3T3 cells (CRL
1658; American Type Culture Collection) were grown in DME
containing 10% (vol/vol) calf serum (Sigma-Aldrich) and 50 U/ml
penicillin and streptomycin. The packaging cell line 293GPG was
grown in DME supplemented with 10% (vol/vol) heat-inacti-
vated FCS, 2 mmol/liter glutamine, 50 U/ml penicillin and
streptomycin (GIBCO BRL), tetracycline (1 
 
m
 
g/ml), puromycin
(2 
 
m
 
g/ml), and G418 (0.3 mg/ml) (all from Sigma-Aldrich).
 
Generation of DCs from Murine Bone Marrow Cells.
 
Bone mar-
row was flushed from the long bones of the hind limbs of 10–14-
wk-old female C57BL/6 mice. Upon depletion of erythrocytes,
the cells were cultured in DC medium (DMEM supplemented
with 10% inactivated FCS, 2 mmol/liter glutamine, 10 mmol
Hepes-buffered saline, 100 mmol nonessential amino acids, 100
U/ml penicillin, 100 
 
m
 
g/ml streptomycine, 5 
 
3 
 
10
 
2
 
5
 
 
 
m
 
M 2-ME
(GIBCO BRL), 500 U/ml recombinant murine GM-CSF, and
500 U/ml murin IL-4 (both from Sigma-Aldrich) (23). On day 7
of culture, released mature nonadherent cells with the typical fea-
tures of DCs were used for in vivo studies. For phenotypic analy-
sis, the expression of the cell surface markers CD11c, CD80,
CD86, MHC class II, and intercellular adhesion molecule 1 was
tested using commercially available mAbs and appropriate isotype
control antibodies (all from BD PharMingen). More than 90% of
the cells showed high expression of these markers while they
 
were negative for expression of CD3, B220, and GR-1. In some
experiments, the capacity of DCs to initiate a mixed lymphocyte
reaction was also confirmed.
 
Transduction of DCs with Retroviral and Adenoviral Constructs.
 
For studies involving retroviral-mediated gene transfer, CMMP,
a novel derivative of MFG, was used. In this vector, the murine
leukemia virus (MLV) LTRs are replaced with the corresponding
myeloproliferative sarcoma virus LTRs and the normal MLV
tRNA primer binding site is replaced by a glutamine tRNA
primer binding site. In experiments requiring coexpression of a
gene product and a reporter gene (green fluorescent protein
[GFP]), bicistronic CMMP viruses were created by insertion of
the internal ribosomal entry site (IRES)-GFP sequence from the
plasmid MSCV2.2-IRES-GFP (gift from B. Sha, University of
California, San Francisco, CA) downstream of the site for inser-
tion of sequences in CMMP. Concentrated vesicular stomatitis
virus G protein (VSV-G)-pseudotyped retroviral particles were
generated via transient transfection of the 293GPG packaging cell
line and ultracentrifugation as described previously (24). For ret-
roviral transductions, 10 
 
m
 
l of high titer viral particles (5 
 
3 
 
10
 
8
 
 to
5 
 
3 
 
10
 
9
 
/ml) was added to 1 ml of DC cultures on days 2 and 4
(in the presence of 8 
 
m
 
g/ml polybrene). The DCs were pre-
cooled, incubated with the virus at 4
 
8
 
C for 3–4 h, and then trans-
ferred to 37
 
8
 
C incubators.
For studies involving adenoviral gene transfer, replication-defi-
cient E1/E3-deleted adenoviral vectors were used, in which tran-
scription of the desired coding sequence was driven by a CMV
promoter (25). DCs were infected by exposure to adenoviral par-
ticles (multiplicity of infection 100) for 3–4 h at 37
 
8
 
C immedi-
ately before use. Expression of human MAGE-1 was confirmed
by immunoblotting with the MAGE-1–specific mAb MA-454
(gift of L. Old, Ludwig Institute for Cancer Research, New York
Branch at Memorial Sloan-Kettering Cancer Center, New York,
NY) (26). 48 h after transduction with recombinant adenoviral
particles DCs were lysed, and 10 
 
m
 
g of protein extract, as deter-
mined by a modified Lowry assay (detergent-compatible protein
assay; Bio-Rad), was subjected to SDS-gel electrophoresis (12%
polyacrylamide gel) in reducing conditions and blotted onto
polyvinylidine difluoride membrane (Bio-Rad). Equal protein
loading was confirmed by Coomassie staining.
 
Tumor Studies.
 
Tumor cells were treated with trypsin,
washed twice in HBSS (GIBCO BRL), and injected in 0.2–0.5
ml of HBSS either subcutaneously (solid tumor model) or intra-
venously in the tail vein (lung metastasis model). In the solid
tumor model, the development of tumors was monitored every
3–4 d. The mice were killed when the sum of the two perpendic-
ular tumor diameters reached 30 mm, or when ulcerating lesions
were detected. Statistical survival differences were evaluated with
the Wilcoxon rank sum test, using JMP3.1.5 software (SAS Insti-
tute). In the short-term experiments, tumor size was measured
every 2 d and the tumor volume was estimated using the follow-
ing formula: (short diameter)
 
2
 
 
 
3
 
 long diameter 
 
3
 
 0.52.
 
Generation of CTL Cultures and IFN-
 
g
 
 Release Assay.
 
Animals
were immunized with 10
 
6
 
 DCs administered subcutaneously into
hind limbs and forearms. 4 d later, regional LNs were harvested
and T cells were purified by negative depletion of B cells and
APCs using magnetic beads (pan IgG Dynabeads; Dynal). T cells
were then restimulated with irradiated B16M-CD80 cells (16 Gy)
at a cellular ratio of 20:1 in the presence of recombinant human
IL-2 (20 U/ml; Sigma-Aldrich). After 5 d, 2 
 
3 
 
10
 
5
 
 viable T cells
were incubated with 5 
 
3 
 
10
 
4
 
 target cells in 96-well plates for 24 h.
The IFN-
 
g
 
 concentration in the supernatant was determined by
ELISA, using commercially available reagents (Endogen). 
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In Situ Analysis of DCs in LNs.
 
To study the homing of DCs
into draining LNs, CMMP-GFP and CMMP-GM-CSF-IRES-
GFP–transduced DCs were sorted for green fluorescence in a
Becton Dickinson FACScan™ and additionally stained with
5-(and-6)-([{4chloromethyl}benzoyl]amino)tetramethylrhodamine
(CMTMR) in the case of GM-CSF–secreting DCs, and 5-chlo-
romethylfluorescein diacetate (CMFDA) in the case of CMMP-
GFP–transduced cells (both from Molecular Probes) according to
the manufacturer’s guidelines. Immediately before subcutaneous
injection, both populations were mixed at a ratio of 1:1. 1.25 
 
3
 
10
 
6
 
 cells were then injected subcutaneously at four sites into the
calves and forearms, and regional LNs were dissected after 24 and
48 h, respectively. The LNs were embedded into OCT Com-
pound 4583 (Sakura) and frozen in liquid nitrogen. 10-
 
m
 
m cryo-
sections of individual LNs were fixed in 3.7% formaldehyde and
visualized with an MRC-1024 laser scanning confocal imaging
system (Bio-Rad). Excitation wavelengths were 488 and 522 nm,
respectively, using emission filters of 522 and 598 nm. Cytologi-
cal preparations of the DC mixture were also evaluated to con-
firm the ratio of red and green cells. Both colors could be well
differentiated despite the common underlying green fluorescence
of GFP. For the in situ analysis, green and red cells were counted
independently on each section. LN sections with 
 
$
 
5 fluorescent
cells were included in the scoring. The ratio of green to red cells
was determined on 10–20 sections/LN.
 
Results
 
Establishment of Tumor Model for Evaluation of DC Vac-
cines.
 
To generate a tumor model suitable for vaccination
studies involving genetically modified DCs, murine mela-
noma B16F10 cells were genetically engineered to express
the human MAGE-1, an embryonal antigen that has been
shown to be an immunological target in patients with mel-
anoma (27) via retroviral infection (21). One particular
clonal cell line expressing MAGE-1 (termed B16-MAGE-
1), which showed identical in vivo growth characteristics
to unmodified B16F10 cells, was chosen for use in tumor
challenge and preexisting tumor studies. To generate DCs
expressing MAGE-1, DCs were prepared from murine
bone marrow cells by culture of the cells in the presence of
GM-CSF and IL-4, as described previously (23), and subse-
quently infected with an adenoviral vector encoding
MAGE-1 (see Materials and Methods). A majority of cells
were transduced by adenoviral vector infection, as evalu-
ated with a lacZ-encoding recombinant adenovirus (Ad)
(data not shown).
The ability of MAGE-1–expressing DCs to induce anti-
tumor immunity against MAGE-1–expressing B16F10 cells
was first evaluated in a standard tumor challenge model.
Groups of eight mice were first injected with either 2 
 
3
 
10
 
5
 
 MAGE-1–expressing DC cells, 2 
 
3 
 
10
 
5
 
 MAGE-1–
expressing EFs (EF-MAGE-1 cells), or 10
 
7
 
 particles of Ad-
MAGE (an adenoviral vector encoding MAGE-1) subcuta-
neous in the abdominal wall. Then, they were challenged
with either 10
 
6
 
 B16-MAGE-1 or the parental B16F10 cells
12 d later. As shown in Fig. 1, vaccination with MAGE-1–
expressing DCs protected a significant number of the mice
against challenge with B16-MAGE-1, but did not protect
 
against challenge with the parental B16F10 cells, which do
not express MAGE-1. These results indicate that, as ex-
pected, the vaccination effect of MAGE-1–expressing DCs
is antigen specific. Animals injected with either EF-
MAGE-1 cells or Ad-MAGE-1 showed some protection
against challenge with B16-MAGE-1 cells as well, albeit
weaker than that elicited by MAGE-1–expressing DCs.
 
Comparative Analysis of the Efficacy of Genetically Modified
DCs and Tumor Cells in Preexisting Tumor Models.
 
To com-
pare the relative efficacy of genetically modified DCs and
cytokine-expressing tumor cells, we employed two differ-
ent preexisting tumor models. In the first model, 5 
 
3
 
 10
 
5
 
viable B16-MAGE-1 cells were injected intravenously
into normal C57BL/6 mice. Subsequently, the mice were
“vaccinated” with either 10
 
6
 
 MAGE-1–expressing DC
cells, GFP-expressing DCs, GM-CSF–expressing B16-
MAGE-1 cells, or IL-12–expressing B16-MAGE-1 cells on
days 3 and 7 after injection of tumor. 24 d after injection of
tumor, animals were killed, and macroscopically visible
lung metastases were counted. IL-12–expressing cells were
chosen for study based on reports by others that IL-12
stimulates antitumor activity in preexisting tumor models
(28–30). As shown in Fig. 2 A, vaccination with either
MAGE-1–expressing DCs or cytokine–transduced B16
cells led to a dramatic reduction in the number of pulmo-
nary metastases. Injection with either MAGE-1–expressing
DCs or IL-12–expressing tumor cells led to a significantly
greater reduction in metastases than injection with GM-
CSF–expressing tumor cells. Antitumor immunity against
pulmonary metastases may not necessarily reflect the patho-
physiological mechanisms that govern the elimination of
solid tumors implanted under the skin. Therefore, we also
evaluated the relative efficacy of DC-based vaccines in a
subcutaneous tumor model and included also CD40L–
transduced tumor cells in these studies. 5 
 
3
 
 10
 
5
 
 B16-
Figure 1. DC-Ad-MAGE-1 cells induce specific antitumor immunity.
Groups of eight mice were first immunized with 2 3 105 DCs, EFs retro-
virally transduced to express MAGE-1, or 107 adenoviral particles by sub-
cutaneous injection. After 12 d, the mice were subcutaneously injected
with 106 B16 wild-type (open symbols) or B16-MAGE-1 (filled symbols)
tumor cells. 
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Figure 2. (A) Comparative analysis of DCs and cytokine-transduced
tumor cells in preexisting pulmonary metastasis model. Animals were in-
jected with 5 3 106 tumor cells by tail vein injection. DCs and cytokine-
transduced tumor cell vaccines (5 3 105 cells) were given on days 3 and 7
by subcutaneous injection. All animals (n 5 4/group) were killed on day
24 and the number of macroscopically visible metastases was determined.
Error bars represent SE. (B) Comparative analysis of DCs and cytokine-
transduced tumor cells in preexisting subcutaneous tumor model. Groups
of 10 mice were treated with a single dose of Ad-transduced DCs (106) or
irradiated cytokine-transduced tumor cells (both via subcutaneous admin-
istration) on day 5 after subcutaneous inoculation of 5 3 105 B16-
MAGE-1 tumor cells. (C) MAGE-1 detection in transduced tumor cells
and DCs. 10 mg of cell extract was loaded onto a 12% polyacrylamide gel
and separated by electrophoresis. The 46-kD MAGE-1 protein was de-
tected by the mAb MA454 (arrow).
 
MAGE-1 cells were injected subcutaneously in C57BL/6
animals, and the mice were subsequently injected with
transduced DCs or tumor cells (10
 
6
 
) one time 5 d later. As
shown in Fig. 2 B, 10% of the tumor bearing mice treated
with MAGE-1–expressing DCs showed long-term survival
without clinical evidence of tumor-growth 
 
.
 
90 d after tu-
mor inoculation (
 
P
 
 
 
, 
 
0.001). In contrast, animals treated
with either GM-CSF–, CD40L–, or IL-12–expressing
B16M cells succumbed to growing tumors. As expected,
GFP-expressing DCs provided no therapeutic effect. To
address the question of whether the increased efficacy of
DC-based vaccines may be due to higher expression levels
of the tumor antigen MAGE-1, we determined the relative
amount of MAGE-1 in DCs transduced with adenoviruses
and retrovirally transduced tumor cells. Equal protein
amounts of cell lysates (10 
 
m
 
g) from transduced DCs and
tumor cells were subjected to immunoblotting with the
human MAGE-1–specific mAb MA454. As shown in Fig.
2 C, despite their increased potency as tumor cell vaccines,
the expression level of MAGE-1 in DCs was inferior to
that in B16-derived tumor cells.
 
Transduction with Cytokine-encoding Retroviruses Further
Enhances the Potency of DCs.
 
To determine whether fur-
ther genetic modifications of DCs might improve their ef-
ficacy as therapeutic vaccines, we evaluated the effect of
expressing three gene products known to influence the de-
velopment and/or function of DCs: GM-CSF, TNF-
 
a
 
,
 
and CD40L. For these studies, retroviral vectors were gen-
erated which encoded the individual gene products. In
each vector, a reporter gene, GFP, was also included and
expressed through the use of IRES sequences in order to
permit the normalization of transduction efficiencies ob-
tained with the different cytokine-encoding viruses. An ad-
ditional virus that only encoded GFP was also generated for
use as a control. Using an optimized method for transduc-
tion (see Materials and Methods), 
 
z
 
20–50% of DCs could
be routinely transduced (Fig. 3 A). In the case of DCs engi-
neered to express either GM-CSF or TNF-
 
a
 
, ELISA assays
indicated the expression of 
 
z
 
500 pg GM-CSF and 1,000
pg TNF-
 
a
 
 per 10
 
6
 
 cells/d, respectively.
Fig. 3, B–E, shows the results of four independent ex-
periments in which the therapeutic efficacy of different ge-
netically modified DC preparations was compared. In each
experiment, the DCs used for vaccination were retrovirally
transduced either with a control virus (CMMP-GFP), or
with a retrovirus encoding a cytokine before transduction
with Ad-MAGE-1. DCs transduced by the different bicis-
tronic viruses were normalized for the percentage of GFP-
expressing cells, and equal numbers of GFP
 
1
 
 cells were
used for vaccination. In a first experiment, the relative effi-
cacy of retrovirally transduced DCs was evaluated by mea-
suring the tumor progression after a single subcutaneous
administration of 10
 
6
 
 DCs. In comparison to GFP-trans-
duced control DCs, a significant effect of DCs that were
engineered to express GM-CSF, TNF-
 
a
 
, or CD40L was
noted (Fig. 3 B). The following experiments show Kaplan-
Meier graphs and reflect long-term survival. In some ex-
periments, additional groups of mice were immunized with 
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Figure 3. Retroviral transduction of DCs enhances
their efficacy as therapeutic tumor vaccines. (A) FACS®
profile of DCs transduced with the retrovirus CMMP-
GFP. The fluorescence is compared with nontransduced
DCs. (B) Mice with preexisting B16-MAGE-1 tumors
(n 5 5/group) were immunized on day 5 after tumor in-
oculation with 106 DC subcutaneously. Error bars repre-
sent the SE of the mean. (C–E) Kaplan-Meier survival
graphs showing long-term tumor-free survival. Groups
of 10 mice were treated with a single dose of 106 DCs
(in E, 1 group received 3 injections in weekly intervals)
or irradiated cytokine-transduced tumor cell vaccines
(106) 5 d after subcutaneous injection of 5 3 105 B16-
MAGE-1 tumor cells. P values are determined by statis-
tical comparison against the survival of mice treated with
DC-Ad-MAGE-1 cells.
 
the cytokine-transduced B16-MAGE-1 cells to provide ad-
ditional points of comparison. As shown in each indepen-
dent experiment, vaccination with DCs expressing only
MAGE-1 (and GFP, the reporter gene product) led to the
long-term tumor-free survival of 10–20% of the animals
(Fig. 3, C–E). As shown above in Fig. 2 B, vaccination
with GM-CSF–transduced B16M cells provided no thera-
peutic efficacy in this preexisting tumor model, and suc-
cessful vaccination was dependent on MAGE-1 expression
by DCs. In contrast to vaccination with only MAGE-1–
expressing DCs, DCs that additionally expressed GM-CSF,
CD40L, or TNF-
 
a
 
 appeared to significantly improve the
therapeutic efficacy of the vaccination. Whereas the long-
term survival benefit of GM-CSF–transduced DCs reached
statistical significance (DC-GM-CSF versus DC-GFP,
 
 P 
 
5
 
0.008, Fig. 3 C), the improved survival curve of mice
treated with CD40L- and TNF-
 
a
 
–transduced DCs only
reached statistical significance if the data from two experi- 
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ments were pooled (e.g., experiments shown in Fig. 3, C
and D;
 
 P 
 
#
 
 0.05). It remains to be determined from larger
studies whether one of the three cytokines will prove to be
superior to the others.
Not surprisingly, the long-term tumor-free survival of
vaccinated animals also appeared to depend on the fre-
quency of vaccinations and the numbers of DCs adminis-
tered. Best results were seen in mice that received either
repetitive doses (Fig. 3 E) or increased numbers of trans-
duced DCs (data not shown). In these experiments, up to
70% of animals showed long-term tumor-free survival.
Furthermore, the effect of GM-CSF was dependent on the
antigen presentation of MAGE-1 in DCs, as the adminis-
tration of DCs transduced with GM-CSF and GFP did not
result in prolonged survival (not shown).
 
The Antitumor Effect of GM-CSF–transduced DCs Is Medi-
ated by Antigen-specific T Cells.
 
To further dissect the im-
munologic mechanisms involved in the DC-mediated anti-
tumor response, we employed a T cell-deficient in vivo
system as well as in vitro studies of antigen-specific CTLs.
First, mice deficient for either CD41 or CD81 subsets of T
lymphocytes were inoculated with B16-MAGE-1 tumor
cells and subsequently immunized with GM-CSF–trans-
duced DCs. As shown in Fig. 4 A, the tumors in both
CD42/2 and CD82/2 deficient animals grew as fast as the
tumors in C57BL/6 wild-type mice immunized with con-
trol transduced DCs, indicating that the antitumor immu-
nity induced by GM-CSF–transduced DCs is mediated
both by CD41 and CD81 T cells. Second, we analyzed
MAGE-1–specific T cells after immunization with various
DC vaccines. Upon subcutaneous administration of GM-
CSF– and GFP-transduced DCs, T cells were purified from
draining LNs and restimulated in vitro using B16-MAGE-
1-CD80 cells, according to a previously published protocol
(31). The cells were then reincubated with B16 wild-type
cells or B16-MAGE-1 cells. We measured the concentra-
tion of INF-g as an indicator for CTL activity. Although
control DCs gave rise to some CTL activity (potentially
due to in vitro priming by residual DCs), DC-Ad-MAGE-1
clearly induced a MAGE-specific CTL response (Fig. 4
B). This effect was significantly stronger in animals immu-
nized with GM-CSF–transduced DCs, indicating that DCs
retrovirally transduced with GM-CSF–encoding constructs
induce a stronger antigen-specific T cell response. On his-
tological examination of hematoxylin and eosin–stained tu-
mor sections, we noted an increased inflammatory response
and tumor cell necrosis upon vaccination with DC-
CMMP-GFP-Ad-MAGE-1, which was even more pro-
nounced in animals that received DCs engineered to se-
crete GM-CSF (data not shown).
Effects of GM-CSF Expression on In Vivo Properties of Ge-
netically Modified DCs. Based on the observed effects of
Figure 4. (A) Antitumor immunity of transduced DCs is
mediated by CD4 and CD8 cells. 5 3 105 tumor cells were
subcutaneously injected in CD42/2, CD82/2, and con-
genic wild-type mice (n 5 5/group). A single dose of DCs
(106) was given on day 5 after the inoculation of tumor
cells. (B) Enhanced cytotoxic T cell activity after immuni-
zation with GM-CSF–transduced DCs. After vaccination
with genetically transduced DCs, T cells were purified
from draining LNs, restimulated in vitro, and incubated
with B16 wild-type (white bars) or B16-MAGE-1 (black
bars) target cells in triplicates. IFN-g was measured in the
supernatant by ELISA.1705 Klein et al.
GM-CSF expression on the therapeutic efficacy of geneti-
cally modified DCs, we next asked whether the expression
of GM-CSF influenced the behavior of the cells in vivo in
any discernible way. We reasoned that the increased effi-
cacy of GM-CSF-transduced DCs might be mediated by
increased survival of those cells that produce their growth
factor in an autocrine fashion. Therefore, we quantified the
number of GM-CSF–transduced DCs in situ. To account
for potential confounding variations between different ani-
mals, we used a mixture of GM-CSF– and GFP-transduced
DCs so that the number of GFP control transduced DCs
served as an internal standard. For these studies, DCs
expressing either no cytokine (CMMP-GFP–transduced)
or GM-CSF (CMMP-GM-CSF-IRES-GFP–transduced)
were first sorted for expression of GFP. GM-CSF–trans-
duced DCs were then stained with the CellTracker™ dye
CMTMR (red fluorescence). CMMP-GFP–transduced
DCs were labeled with the CellTracker™ dye CMFDA
(green fluorescence) to assure higher fluorescence intensity
and an appropriate labeling control. Both populations of
cells were mixed to equal ratios immediately before their
subcutaneous injection. After 24 and 48 h, the animals were
killed, and the ratio of GM-CSF– to GFP-transduced DCs
was determined in the draining LNs. This ratio was compared
with the ratio of the cells before injection by confocal mi-
croscopy. As shown in Fig. 5, we detected a proportionally
higher number of GM-CSF–transduced DCs in all LNs ex-
amined. Similar results were seen when GM-CSF–transduced
cells were labeled with the green dye and GFP-transduced
cells were stained in red, excluding the possibility of dye ar-
tifacts. This finding is consistent with the hypothesis that
DCs that secrete their growth factor GM-CSF either home
more efficiently to draining LNs, continue to divide in
vivo, or generally persist longer in vivo.
Discussion
In light of the many promising immunotherapeutic strat-
egies that have been evaluated in preclinical studies over the
past few years, there has been an increasing need to define
the most promising candidate therapies for clinical studies.
The studies described here provide an important compari-
son of two commonly used strategies for inducing antitu-
mor immunity which appear to have a related mechanism
of action. The major conclusion from our studies is that
DCs engineered to express a surrogate tumor antigen elicit
a significantly stronger antitumor immunity than tumor
cells that coexpress that same antigen and one of several im-
munostimulatory cytokines. Moreover, we have shown
that it is possible to further enhance the immunotherapeutic
potential of DCs by additional genetic modifications.
Previous comparative analyses of DC-mediated T cell
priming have included a determination of the relative effi-
ciency of presenting antigen on DCs via conventional puls-
ing of cells with protein or peptide versus expression of the
antigen through the use of vaccinia or Ad vector (32), as
well as assessments of the relative efficacy of transfected DCs
versus transfected fibroblasts or vaccination with naked
DNA (33). In the most relevant comparison to the studies
reported here, Ashley et al. compared the efficiency of im-
munostimulation by DCs pulsed with either tumor extracts
or tumor RNA to vaccination by GM-CSF–modified tu-
mor cells in an intracranial tumor challenge model (18).
While no significant differences were observed in their
studies, it is likely that this is due to the use of a less stringent
tumor challenge model than those used in the current study,
as GM-CSF–expressing cells possessed readily detectable ac-
tivity in their model. In both our own published (9) and
unpublished studies (our unpublished data), we have found
that GM-CSF possesses relatively little activity in most pre-
existing tumor models in which the vaccine is administered
.3 d after tumor inoculation.
There have also been a limited number of recent reports
that the engineered expression of specific gene products by
DCs, such as IL-7 (34) and lymphotactin (35), can improve
their immunostimulatory function. For our studies, we
chose to evaluate the activity of several gene products, GM-
CSF, TNF-a, and CD40L, known to be critically involved
in the differentiation, activation, and maturation of DCs.
For example, GM-CSF has been identified as a critically im-
portant growth factor for DCs (23) and seems to be impor-
tant in maintaining the efficient presentation of soluble anti-
gen (36). Members of the TNF family are known to
activate DCs. TNF-a contributes to both DC maturation
(37) and activation (38). CD40L has equally been shown to
promote DC maturation from human hematopoietic pro-
genitor cells (39–41). Signaling via CD40 upregulates the
expression of costimulatory molecules (39, 42) and may be
the key event that enables the DCs to stimulate T killer cells
Figure 5. GM-CSF–transduced DCs give rise to higher cell counts in
draining LNs. DCs were retrovirally transduced with CMMP-GFP or
CMMP-GM-CSF-IRES-GFP and sorted for GFP1 expression.
CMMP-GFP–transduced cells were additionally stained with the green
CMFDA CellTracker™ dye; CMMP-GM-CSF-IRES-GFP1 cells were
stained with the red fluorescent CMTMR CellTracker™ dye. Both
populations were mixed immediately before subcutaneous injection. An-
imals were killed after 24 and 48 h and the ratio of green to red cells was
determined in three draining LNs. The error bars indicate the SD of
10–20 sections/LN.1706 Comparison of Dendritic Cell and Tumor Cell–based Cancer Vaccines
(43–45). Our finding that the engineered expression of ei-
ther of the three molecules tested led to significantly im-
proved biological activity suggests that the optimal in vivo
behavior of DCs may be quite dependent on a pattern of
normal endogenous gene expression not easily maintained
after ex vivo manipulation of the cells. This notion is consis-
tent with a variety of studies by others that suggest that opti-
mal DC function can be highly dependent on the precise
methodology used for their generation and expansion (46,
47). While the precise explanation for the enhanced immu-
nogenicity of GM-CSF–transduced DCs (or cells transduced
by TNF-a or CD40L viruses) remains to be determined,
our dye-tracking experiments indicate that GM-CSF ex-
pression results in more transduced DCs reaching the LN.
This could be due to several mechanisms, including direct
effects upon the in vivo migration characteristics of injected
DCs (48) and/or their resistance against apoptosis (49, 50).
Future experiments will address these hypotheses.
Unfortunately, a critical issue that cannot be easily an-
swered by any preclinical studies, including those pre-
sented here, is whether a general statement can be made
about the relative efficacy of antigen-specific vaccination
strategies, such as vaccination with antigen–expressing
DCs, and strategies that aim to mount an immune re-
sponse against a diversity of antigens, as is the goal of vac-
cination with genetically modified tumor cells. Further-
more, we are aware that our data are based on the
introduction of a xenogeneic protein and that it may be
even more difficult to induce antitumor immunity against
autologous antigens. However, in light of the current
studies and the promising clinical studies involving the use
of cytokine-expressing tumor cells, parallel clinical studies
that evaluate the relative efficacy of transduced tumor cell
vaccine and genetically modified DCs would appear to be
warranted. In addition, our studies suggest that it will be
important to directly test in patients whether DCs geneti-
cally modified to express both a target tumor antigen and a
specific cytokine, such as GM-CSF, will show improved
biological activity relative to strategies involving DCs pre-
pared in other ways.
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